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Abstract
Background: To describe structural and functional changes associated with diabetic macular oedema (DMO) treated with
intravitreal bevacizumab over 24 months.
Methods: A post-hoc analysis of the data of 34 patients that completed 24 months follow-up in the intravitreal
bevacizumab arm of a prospective, randomized controlled trial (BOLT study) was performed. The outcome measures
previously used in clinical trials of intravitreal ranibizumab in DMO were employed to describe the visual acuity and macular
thickness changes at 12 and 24 months.
Results: The standard outcomes of mean change in best corrected visual acuity (BCVA) and central macular thickness (CMT)
in participants treated with bevacizumab were comparable to those reported in association with ranibizumab. However,
exploratory analyses showed that thick maculae at baseline defined as CMT of$400 mm, remained significantly thicker than
those ,400 mm with intensive bevacizumab therapy, despite a comparable gain in visual acuity at both 12 and 24 months.
The proportion of subjects that attained a dry macula doubled in both CMT groups between the 12 and 24-month time-
points.
Conclusions: These findings provide valuable information both for clinical practice and trials. Further studies are required to
investigate the impact of intravitreal bevacizumab on retinal thickness profiles in DMO.
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Introduction
Diabetic macular oedema (DMO) is one of the leading causes of
visual impairment in the working age group [1]. Laser photoco-
agulation has been the mainstay of treatment of this condition [2].
The introduction of molecular inhibitors of vascular endothelial
growth factor (VEGF), such as ranibizumab and bevacizumab, as
approved and off-label therapy for DMO respectively, has
revolutionised the management of DMO, with improved visual
outcomes compared to laser photocoagulation [3,4,5,6]. Analyses
of several well-conducted clinical trials of ranibizumab in DMO
have provided insights into outcome measures that are valuable to
clinicians, health economists, funders and clinical trialists [7,8].
For example, the stratification of DMO and response to treatment
in terms of macular thickness has helped to improve our
understanding of the effect of ranibizumab.
In comparison, there are fewer randomised clinical trials of
bevacizumab in DMO, with smaller patient numbers. Moreover,
the inclusion criteria and outcome measures used in these trials are
not comparable enough to readily allow stakeholders to reach an
informed decision about its use [9]. To begin to address this we
have undertaken a detailed analysis of the results of our clinical
trial on bevacizumab for DMO (BOLT study) using the accepted
outcome measures and predictive factors that have been published
in the ranibizumab studies [4,8,10,11].
The objectives of the study were to conduct exploratory analyses
to provide further detailed descriptive statistics of the outcome
measures of the bevacizumab arm of the BOLT study in line with
the DRCR.net study on ranibizumab in DMO [7,8] and examine
the factors that are associated with change in visual acuity and
central macular thickness at 24 months.
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Methods
Ethics Statement
The BOLT study complied with the Declaration of Helsinki.
The research protocol was approved by the Moorfields and
Whittington Ethics Committee 07/Q0504/28.
Synopsis of the BOLT Study
The details of the BOLT study and the results based on the
standard outcome measures at 12 and 24 months have previously
been reported [10,11]. In brief, the BOLT study was a prospective
randomised 2-year single-centre trial that enrolled patients with
persistent centre-involving clinically significant DMO after at least
1 prior macular laser treatment (MLT) and compared the efficacy
of intravitreal bevacizumab (1.25 mg/50 ml given at 6 weekly
intervals) to MLT at 4 monthly intervals. Primary outcome was
assessed at 12 months [10] and secondary outcomes at 24 months
[11]. Patients with best-corrected visual acuity (BCVA) in the
study eye between 35 and 69 ETDRS letters at 4 m (Snellen
equivalent $6/60 or #6/12) and centre-involving DMO with
CMT on Stratus optical coherence tomography (OCT) of
$270 mm were included. In the bevacizumab arm, patients
received 3 mandatory injections at 6 weekly intervals followed by
an OCT-guided re-treatment protocol. The study reported that a
median of nine injections in the first 12 months resulted in a
median gain of 8 letters in 42 patients in the bevacizumab arm
[10]. Following a median of a further 4 injections in the second
year, the median gain of visual acuity from baseline was 9 letters in
the 37 patients that continued in the bevacizuamb arm in the
second year [11]. In the bevacizumab arm, the median gain of
vision was 9 ETDRS letters and 49% gained 10 letters while 32%
gained 15 letters at 24 months. The mean reduction in CMT was
146 mm.
Exploratory Outcome Measures
The functional outcome measures of mean change in BCVA,
proportion of patients with gain or loss of visual acuity of 10, 15
and 30 letters at 12 and 24 months have previously been reported
[10,11]. We further evaluated the proportion of patients with .73
letters (Snellen equivalent.6/12) at 12 and 24 months. In
addition, the percent reduction in visual acuity deficit was
assessed. Visual acuity deficit was defined as 84 letters (Snellen
equivalent 6/6) minus baseline visual acuity. The percentage
deficit was calculated as the percentage change in visual acuity
from baseline divided by the visual acuity deficit [7,8]. Patients
were also stratified into 2 groups based on the UK definition of
visual impairment at baseline: ,54 letters and $54 letters [12],
and the above outcome measures were compared in the two
groups.
The anatomical change on OCT has been previously reported
as the mean change in CMT (central 1000-mm diameter area) as
shown on the automatic thickness analysis map [10,11]. The
StratusOCT (Carl Zeiss Meditec, Inc., Dublin, CA) images, using
the Radial Lines protocol of six high-resolution B-scans (512 A-
scans per 6-mm B-scan) or the Fast Macular Thickness protocol of
six lower-resolution B-scans (128 A-scans per 6-mm B-scan) were
used. Scans with a signal-to-noise ratio of $6 were included. The
coefficients of repeatability are less than 8% in healthy subjects
and less than 9% in patients with diabetic macular oedema [13].
We further explored the proportion of patients with ,250 mm
(‘dry macula’) at 12 and 24 months. Trials for diabetic retinopathy
have defined CMT values .250 mm as significant for macular
edema to qualify for various trials [3,8,10]. In order to control for
any ceiling or floor effect, the percentage change in CMT was also
considered as a treatment response. This was calculated as the
change in thickness divided by the baseline thickness.
Excess retinal thickness was defined as baseline CMT minus
201 mm (normative value of CMT). The percentage change in
excess retinal thickness was calculated as the percentage of change
of CMT from baseline divided by excess retinal thickness [7,8].
A one log step change in logOCT is 20% change in CMT and
this approximates to twice the error of measurement for any
degree of retinal thickening on OCT while a 2 log step change is
generally considered clinically important at any level of visual
acuity [8,14]. Logarithmic transformation of the OCT retinal
thickness helps normalise skewed distribution of these values. This
exploratory measure was evaluated at 12 and 24 months in our
cohort.
In order to probe the drug-related structure-function relation-
ship, we used the composite score used in the DRCR.net analyses,
defined as a 10 letter improvement with at least a 20% reduction
in CMT [8]. This was assessed at 12 and 24 months.
In keeping with previously described ranibizumab-associated
outcomes, we also classified the anatomical responders as those
with evidence of a CMT reduction of $20% at 4 and 12 months
[8]. In brief, early and consistent responders were those who
showed $20% reduction in CMT at 4 months and this effect was
sustained at 12 months. Early and inconsistent response was
defined as those that showed the aforementioned early response
but failed to maintain it at 12 months. Slow and variable
responders are those who did not respond at 4 months but
responded at 12 months. Non-responders are those that did not
show any response at 4 months or 12 months [8].
At 24 months, we further classified the anatomical responders
based on the change of CMT$20% from 12 months into three
groups: (i) sustained responders were those that showed a further
$20% reduction in CMT at 24 months; (ii) stable response was
defined as a change of CMT of 619% from 12 months; and (iii)
late poor responders were defined as those in whom CMT
increased by $20% at 24 months.
The participants were also stratified based on baseline CMT
into ,400 mm or $400 mm based on the fact that ranibizumab is
most cost-effective when given to patients with CMT$400 mm
than ,400 mm [15] and the above outcome measures were
compared between these two groups.
Predictive Factors
The baseline data from the BOLT study that were analysed
include age, gender, visual acuity, macular thickness, duration of
diabetes, HbA1c (glycosylated haemoglobin), number of previous
laser treatments and diameter and area of the foveal avascular
zone. The dependent variables were final BCVA, change in
BCVA, final CMT and change in CMT.
Statistical Analysis
Only patients that completed the 24 months follow-up were
included in this study. However, baseline characteristics were
compared between this group and the whole cohort recruited to
the bevacizumab arm of the study. Statistical analysis was
conducted utilising association of baseline clinical, OCT, and
fundus photographic variables using STATA. All reported P-
values are 2 sided and a Bonferroni adjustment was made to the
multiple comparisons. P-values of less than 0.05 were taken as
significant. Statistical significance of sample characteristics were
determined using Kruskal-Wallis test for continuous variables and
chi-square for categorical variables. Multiple regression analyses,
using (General Linear Modelling; multivariate ANCOVA) was
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used to determine the factors which may be predictive of
treatment response.
Results
A total of 34 patients completed the 24 month exit assessments
in the bevacizumab arm of the BOLT study and were included in
these analyses. The baseline characteristics of these participants
were comparable to those previously reported for all participants
that were randomised to the bevacizumab arm [10]. The median
visual acuity was 58.5 letters (25th percentile, 53 letters and 75th
percentile 64.5 letters). The mean (SD) was 57.6 (7.6) letters.
Table 1 shows the BCVA and CMT at baseline, 12 and 24
months. Although all participants in this trial had a baseline
BCVA in the study eye that was below the legal requirement to
drive in the United Kingdom, treatment with bevacizumab
enabled approximately 25% of them to meet the requirement
based on final visual acuity being more than 73 letters (Snellen
acuity better than 6/12) in the study eye. Similarly, a BCVA of less
than 54 letters (Snellen equivalent of 6/24) is the level of vision
classified as visual impairment. The proportion of eyes with vision
,54 letters reduced by 50% and 60% at 12 months and 24
months respectively.
The median central subfield thickness was 486.5 mm (25th
percentile, 387; 75 percentile, 525). Despite a median of 9
injections in the first year, only 17.6% attained ,250 mm at 12
months and this proportion doubled at 24 months (35%).
However, the proportion of participants with .600 mm remained
unchanged throughout the study period. The mean number of
injections given to the patients with a dry macula at 24 months was
not significantly different to those that continued to be thickened.
Visual Acuity Outcome at 12 and 24 Months
The overall mean gain of visual acuity of these participants was
5.2 letters (one ETDRS line of vision) at 12 months and 7.8 letters
at 24 months. The changes in various categories of visual acuity
are shown in Tables 2 and 3. Participants with baseline BCVA of
less than 54 letters gained more letters at 12 months than those
with $54 letters. The trend continued at 24 months when a mean
gain of 2 lines of vision was observed in the group with lower
baseline visual acuity (,54 letters). However, none of the
participants with lower baseline vision reached driving vision.
Participants with better baseline vision ($54 letters) achieved
better final visual acuity with 38% achieving driving standard
BCVA at 24 months.
Change in Central Macular Thickness
The mean reduction in CMT of the cohort was approximately
121 (SD 117) mm at 24 months and was independent of baseline
BCVA. Seventy-nine percent still had centre involving macular
oedema at 12 months, decreasing to 65% at 24 months. The
proportion of participants with a CMT$300 mm at 12 and 24
months were 65% and 56% respectively. Participants with a
CMT$400 mm remained significantly thicker at 12 and 24
months, than those with CMT,400 mm. The mean percentage
reduction in excess macular thickness was comparable in the two
categories of baseline macular thickness (300 and 400 mm) at both
time-points (Tables 2 and 3).
There was no significant correlation between baseline visual
acuity or baseline CMT with change in visual acuity or change in
macular thickness. Thirty percent of the participants achieved the
aforementioned composite score of a gain of 10 or more letters
associated with a .20% reduction of CMT, at month 12 and 24.
Patterns of Evolution of Macular Oedema Over Time
The findings are summarised in Table 4. At 12 months, 30% of
the participants responded after 3 loading injections and
maintained that effect to 12 months (‘Early and consistent’
pattern), associated with the best visual outcome compared to
other patterns of response. However, half of these participants
then failed to maintain this effect at 24 months.
Associations between Baseline Characteristics and
Change in Visual Acuity and Central Macular Thickness
Table 5 shows the fully adjusted effect size and confidence
intervals of associations between baseline characteristics and
change in visual acuity and macular thickness at 24 months. We
identified that better baseline visual acuity was associated with a
better visual acuity at both 12 and 24 months, but did not
influence the change in visual acuity.
Table 1. The baseline, 12 and 24 months best corrected visual acuity and central macular thickness broken down by categories.
ETDRS letters Baseline N (%) N=34 12 months N (%) N=34 24 months N (%) N=34
.73 0 (0) 3 (8.8) 9 (26.5)
69–73 3 (8.8) 7 (20.6) 6 (17.6)
59–68 14 (41.2) 15 (44.1) 12 (35.3)
49–58 11 (32.4) 5 (14.7) 2 (5.9)
39–48 6 (17.6) 4 (11.8) 4 (11.8)
#38 0 (0) 0 (0) 1 (2.9)
CMT mm
,250 0 (0) 6 (17.6) 12 (35.2)
,300 1 (2.9) 11 (32.4) 15 (44.1)
301–400 11 (32.4) 8 (23.5) 7 (20.6)
401–600 17 (50.0) 11 (32.4) 8 (23.5)
.600 5 (14.7) 3 (8.8) 4 (11.8)
ETDRS –early treatment diabetic retinopathy study; CMT- central retinal macular thickness.
doi:10.1371/journal.pone.0072755.t001
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Discussion
This exploratory investigation of the BOLT study provides
detailed descriptive analyses of the changes in visual acuity and
central macular thickness and predictive factors of response of
DMO to bevacizumab over 24 months. We highlight here that all
bevacizumab trials to date are of relatively small sample size
compared to the ranibizumab trials thereby making comparison
challenging. However, as bevacizumab is by far the most
commonly used antiVEGF agent globally, it is important that this
randomised controlled trial of bevacizumab in DMO with 24
months follow-up be analysed in the format used in the
ranibizumab studies [7,8] to better inform clinicians, patients
and funders, rather than solely make assumptions that the drugs
are similar for treating DMO based on published trials comparing
the 2 drugs in age related macular degeneration.
The overall functional outcomes of the bevacizumab arm of the
BOLT study at 12 and 24 months are similar to that of the
ranibizumab studies [4,7,8] despite using a 6 weekly interval
loading phase and different re-treatment criteria. Nevertheless the
re-treatment criteria in the BOLT, RESTORE and DRCR.net
studies were designed on the same principle of initiation phase
followed by individualised PRN dosing schedule based on disease
progression as judged by visual acuity and OCT changes, with a
low threshold for re-treatment. In the RESTORE study, from
month 3 to 11, monthly injections were given until vision was
stabilised (i.e. at the 2 last consecutive visits no BCVA
improvement observed due to ranibizumab or BCVA.84 letters).
Injections were re-initiated if there was BCVA decrease due to
DMO progression. In DRCR.net study, re-injection was done in
all visits in which there was an evidence of improvement. If success
or failure criteria were met it was left to the investigator’s
discretion to re-inject. The visual acuity eligibility criterion of the
Table 2. Outcomes measures in terms of visual acuity and anatomical changes at 12 months from baseline.
All patients N=34
VA ,54 letters
N=10 VA $54 letters N=24 CMT ,400 mm N=12$ CMT $400 mm N=22
Baseline median VA (range) 58.5 (42–69) 47.5 (42–53) 60.0 (54–69) 61.0 (53–69) 57.0 (42–69)
Median change in VA (range) 8.0 (218 to 16) 8.5 (23 to 16) 7.0 (218 to 15) 7.0 (210 to 13) 8 (218 to 16)
Median final visual acuity
(range)
63.5 (44–79) 57.5 (44–68) 67.0 (47–79)* 67.0 (47–78) 62.0 (44–79)
Proportion with final visual
acuity .73 letters
3 (8.8) 0 (0) 3 (14.3) 1 (8.3) 2 (9.1)
Proportion with $10 letter
gain
11 (32.4) 4 (30.8) 7 (33.3) 3 (25.0) 8 (36.4)
Proportion with ,10 letter
gain
23 (67.6) 6 (60.0) 17 (70.8) 9 (25.0) 14 (63.6)
Proportion with $15 letter
gain
3 (8.8) 2 (20.0) 1 (4.2) 0 (0) 3 (13.6)
Proportion with ,15 letter
gain
31 (91.2) 8 (80.0) 23 (95.8) 12 (100.0) 19 (86.4)
Proportion with $30 letter
gain
0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Proportion with ,30 letter
gain
34 (100) 10 (100.0) 24 (100.0) 12 (100.0) 22 (100.0)
Proportion with $10 letter
loss
1 (2.9) 0 (0) 1 (4.2) 0 (0) 1 (4.5)
Proportion with $15 letter
loss
1 (2.9) 0 (0) 1 (4.2) 0 (0) 1 (4.5)
Proportion with$30 letter
loss
0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Median change in CMT
(range)
2106.5 (2496 to 92) 2182.5 (2496 to 18) 286.5 (2407 to 92) 250.5 (2187 to 20) 2137.5 (2496 to 92)*
Median final CMT
(range)
374.0 (167–663) 436.0 (215–663) 321.0 (167–617)* 286.5 (167–405) 430.0 (173–663)*
Proportion with final CMT
,250 mm
6 (17.6) 1 (11.1) 5 (20.8) 3 (25.0) 3(14.3)
Median % change in excess
retinal thickness
243.3 236.5 243.3 229.7 243.3
Proportion of patients with 2
step reduction of logOCT
n(%)
8(25) 3(33.3) 5 (21.7) 3(27.3) 5(23.8)
Median number of injections
in 12 months (range)
9.0 (5–9) 9.0 (8–9) 8.5 (5–9) 8.5 (5–9) 9.0 (5–9)
BOLD= significant p,0.05;
$
1 missing value; VA-visual acuity; SD- standard deviation; CMT –central macular thickness.
doi:10.1371/journal.pone.0072755.t002
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BOLT study was also different, with a lower visual acuity range of
35–69 letters, unlike the DRCR.net study where 50% of the study
eyes had $66 letters, and 19.8% of the RESTORE patients who a
BCVA of more than 73 letters.
Despite these aforementioned differences in baseline character-
istics, the patterns of response of DMO to ranibizumab and
bevacizumab are very similar when standard outcomes are
assessed. But, this study also highlights important differences that
should be explored in adequately powered larger studies. The
median baseline CMT in the bevacizumab arm in the BOLT
study for patients who exited at 24 months was higher than that of
patients who completed 2 years in the DRCR.net trial, suggesting
that comparisons between the drugs should be made with caution.
However, whilst in the ranibizumab studies [4,7,8] approximately
40% had persistent macular oedema defined as OCT central
subfield $250 mm and only 20%–24% had more than mildly
thickened retina defined as OCT central subfield #250 mm at two
years, the corresponding figures in the bevacizumab arm of the
BOLT study were 65% and 56% respectively. This suggests that
further studies should explore the concept that the ‘drying effect’ of
bevacizumab may be less effective than for Ranibizumab [16].
Despite the fact that greater reductions in thickness were
observed in BOLT participants with macular thickness of
$400 mm compared to those with #400 mm, the mean macular
thickness was still $400 mm at 12 and 24 months, and the
proportion that achieved a dry macula (CMT,250 mm) was
limited to 14% and 27% at 12 and 24 months respectively. Similar
effects were observed in the DRCR.net study. However, the
Table 3. Visual acuity and anatomical outcome measures at 24 months compared to baseline.
All patients N=34
VA ,54 letters
N=10 VA $54 letters N=24
CMT ,400 mm
N=12 CMT $400 mm N=22
Median change in VA (range) 9.5 (29 to 28) 9.0 (29 to 24) 10.5 (29 to 28) 8.5 (29 to 24) 9.5 (29 to 28)
Median final visual acuity (range 67.0 (38–88) 55.5 (38–77) 68.0 (48–88)* 68.0 (48–83) 66.5 (38–88)
Proportion with final visual
acuity .73 letters
9 (26.5) 1 (10.0) 8 (33.3) 4(33.3) 5(22.7)
Proportion with $10 letter gain 17 (50.0) 5 (50.0) 12 (50.0) 6(50.0) 11(50.0)
Proportion with ,10 letter gain 17 (50.0) 5 (50.0) 12 (50.0) 6(50.0) 11(50.0)
Proportion with $15 letter gain 11 (32.4) 4 (40.0) 7 (29.2) 4 (33.3) 7 (31.8)
Proportion with ,15 letter gain 23 (67.6) 6 (60.0) 17 (70.8) 8 (66.7) 15 (68.2)
Proportion with $30 letter gain 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Proportion with ,30 letter gain 34 (100.0) 10 (100.0) 24 (100.0) 12 (100.0) 22 (100.0)
Proportion with $10 letter loss 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Proportion with $15 letter loss 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Proportion with$30 letter loss 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Median % reduction in visual
acuity deficit
36.0 24.0 41.67 34.7 37.7
Median change in CMT (range) 2121.0 (2477 to 177) 2131.5 (2438 to 103) 2122.5 (2477 to 123) 294.0 (2160 to 54) 2169.5 (2477 to 123)
Median final CMT (range) 340.5 (117–852) 381.0 (220–852) 292.0 (117–645) 251.5 (156–2439) 381.0 (117 to 852) ns
Proportion with final CMT
,250 mm
12 (35.3) 2 (20.0) 10 (41.7) 6(50.0) 6(27.3)
Mean % reduction in CMT 256.0 239.9 258.8 268.1 249.3
Proportion of patients with 2 step
reduction of logOCT
15(45.5) 5 (50.0) 10 (43.5) 5(41.7) 10(47.6)
Median number of injections in
year 2 (range)
5.0 (0–9) 5.5 (4–7) 4.0 (0–9) 4.5 (0–9) 5.0 (0–7)
BOLD= significant p,0.05 VA-visual acuity; SD- standard deviation; CMT –central macular thickness.
doi:10.1371/journal.pone.0072755.t003
Table 4. The evolution patterns of diabetic macular oedema at 12 and 24 months.
Patterns of evolution No: of Eyes
Median change in VA
(IQR) at 12 months Response at 24 months
Sustained responders stabilisers Late Poor responders
Early and consistent 10 10.5 (4 to 16) 2 3 5
Early and inconsistent 2 8.5 (8 to 9) 1 0 1
Slow and variable 7 1.0 (218 to 13) 1 4 2
Non responder 3 9.0 (2 to 13) 2 0 1
doi:10.1371/journal.pone.0072755.t004
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proportion with $2 step log improvement in LogOCT was lower
in the BOLT study compared to the DRCR.net study. Although
the BOLT study is a small study, these exploratory analyses
provide support for a comparative study of ranibizumab and
bevacizumab.
Some of these differences may be related to differences in
molecular weight, half-life and degree of retinal penetration of
bevacizumab and ranibizumab based on their structural differ-
ences. However, the importance of these proposed differences is
controversial [17,18,19,20]. Further studies are required to elicit
the optimal therapeutic effect of bevacizumab in different retinal
thickness profiles.
Another noteworthy finding was that eyes with rapid and
consistent response to bevacizumab had the best outcome at 12
months compared to all the other OCT patterns of resolution of
oedema. This is in keeping with the ranibizumab studies [7,8].
However, an increase in macular thickness of at least 20% was
observed in 50% of these participants by 24 months. This
observation mirrors the CATT study, in which persistent fluid at
the macula was more frequently observed in the bevacizumab arm
compared to Ranibizumab [14]. This delayed non-response or
rebound phenomenon also merit further evaluation in future
studies.
The inherent limitation of this study is the small sample size.
Nevertheless, the trends shown in these exploratory analyses justify
further investigation, since they have important implications on
the potential choice of anti-VEGF agent to use in eyes with DMO.
Another limitation is the use of Stratus OCT, a time domain OCT
which is subject to frequent artefacts and lower repeatability
compared to spectral-domain OCT. Further sufficiently powered
clinical trials comparing various antiVEGF agents with at least 24
months follow-up and using spectral domain OCT will better
inform clinicians on subtle differences in the effects on macular
thickness profiles.
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